🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — June 13, 2026

This digest covers two contracts totaling $155.3 million, both civilian (0% defense-related), with an average signal strength of 4.0/10. The dominant award is a $154.9 million GSA office construction contract to privately held Volmar Construction Inc., representing 99.8% of total obligation value and signaling sustained federal investment in NYC office infrastructure despite post-pandemic headwinds. A minor $370,500 sole-source communication equipment contract to Lockheed Martin from the Secret Service offers negligible financial impact but confirms Lockheed's non-competitive access to DHS. Key risk: Volmar's contract is fixed-price incentive with medium pricing risk and no direct public equity exposure, limiting investable upside. Highest-conviction signal is neutral: the GSA contract shows strong execution (67% completion) but offers no public company leverage.

2 total filings
· daily

Contract Deobligations Alert — June 13, 2026

The two contracts analyzed for June 13, 2026, total $155.3 million, with zero defense-related awards, underscoring a purely civilian procurement theme. The dominant signal is a $154.9 million GSA construction contract to private firm Volmar Construction Inc., which, while large, offers no direct public equity exposure. The only public company involved is Lockheed Martin, but its $370,500 Secret Service contract is immaterial to its revenue base. The digest highlights a low-conviction, neutral signal set with no bullish or bearish catalysts, and the key risk is the lack of actionable public-company exposure from the highest-value award.

2 total filings
· daily

Contract Option Exercises — June 13, 2026

The two contract actions on June 13, 2026, total $155.3 million in obligations, entirely civilian (0% defense), with an average signal strength of 4.0/10, indicating low investment materiality. The dominant theme is General Services Administration (GSA) office construction in New York City, driven by a $154.9 million fixed-price incentive contract to privately held VOLMAR CONSTRUCTION INC—representing 99.8% of aggregate value but offering no direct public equity exposure. A small $370,500 sole-source communication equipment award to Lockheed Martin from the U.S. Secret Service signals continued DHS engagement but is immaterial to Lockheed's revenue. The highest-conviction signal is the GSA's sustained investment in federal office space post-pandemic, though the lack of public-company beneficiaries limits actionable equity implications. Key risk: the VOLMAR contract's fixed-price incentive structure exposes the private contractor to execution risk on a long-duration project with 67% completion already recognized.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 13, 2026

This single-contract digest covers a $154.9 million fixed-price incentive award from the General Services Administration (GSA) to privately held VOLMAR CONSTRUCTION INC for office building construction in New York City. The contract is entirely civilian, with zero defense exposure, and carries a neutral signal strength of 5/10 and low materiality of 2/10 due to the private nature of the recipient. The dominant theme is GSA’s continued investment in federal office space in major urban centers, even amid post-pandemic shifts. The highest-conviction signal is the 67% completion rate ($103.7M outlayed), indicating strong execution and consistent cash flow for VOLMAR, but there is no direct public equity exposure. A key risk is the medium pricing risk inherent in the fixed-price incentive structure, which could compress margins if construction costs overrun. Investors should monitor GSA’s broader NYC office portfolio spending for follow-on opportunities that may involve publicly traded construction or facilities management firms.

1 total filings
· daily

High-Value Federal Grants ($5M+) — June 13, 2026

The single contract in this period, a $154.9 million fixed-price incentive award to privately held VOLMAR CONSTRUCTION INC by the General Services Administration (GSA), is entirely civilian and non-defense. While the contract provides long-term revenue visibility (2019-2026) and strong execution (67% completion), its materiality to public equity markets is low due to the contractor's private status. The highest-conviction signal is neutral: the award demonstrates GSA's continued investment in traditional office construction in New York City, but offers no direct public equity exposure. Key risk is the lack of follow-on contract visibility beyond 2027 and potential performance issues under the fixed-price structure.

1 total filings
· daily

General Federal Contracts — June 13, 2026

This single-record digest covers a $154.9 million civilian contract awarded by the General Services Administration (GSA) to privately held VOLMAR CONSTRUCTION INC for office building construction in New York City, with zero defense-related content. The contract is a fixed-price incentive award, with $103.7 million already outlayed (67% completion), signaling strong execution and long-term revenue visibility for the contractor but offering no direct public equity exposure. The dominant theme is GSA's continued investment in federal office infrastructure post-pandemic, though the contract's materiality to public markets is low. Key risk centers on execution under the fixed-price incentive structure and potential subcontractor disputes, while the absence of defense alignment limits sector-wide implications.

1 total filings
· daily

Biotech Small-Cap Approvals — June 12, 2026

During the June 12, 2026 window, the FDA approved 9 non-NME, non-biosimilar (designated 'FALLBACK' type) products, all rated neutral in signal. No new molecular entities or traditional biosimilars were approved, resulting in a flat investment narrative. The dominant cluster is five approvals of TOFACITINIB CITRATE biosimilars from YAOPHARMA CO LTD, ORIENT PHARMA, AUSON, CONCORD BIOTECH LTD, and SAPTALIS PHARMS, signaling an impending wave of generic erosion for Pfizer’s XELJANZ franchise. The highest-conviction signal is the TOFACITINIB CITRATE wave, which is bearish for XELJANZ pricing and market share. Key risk: the rapid, multi-entrant generic entry into the JAK inhibitor market portends significant pricing compression, with potential spillover to other oral JAK inhibitors. The single diagnostic imaging approvals (RADIOMEDIX’s GALLIUM GA-68 GOZETOTIDE and ZENARA’s GADOBUTROL) represent niche genericization of radiopharmaceuticals with limited commercial disruption.

9 total filings
· daily

Big Pharma Approvals — June 12, 2026

During the single-day period of June 12, 2026, the FDA issued one label expansion approval for Eli Lilly's LEBRIKIZUMAB-LBKZ (EBGLYSS), classified as a fallback approval with a bullish signal. No NMEs, biosimilars, or other label expansions were approved, making this a low-activity period with no dominant therapeutic area theme. The highest-conviction signal is Eli Lilly's label expansion for EBGLYSS, which strengthens its immunology portfolio but lacks disclosed commercial details. Key risks include potential competitive pressure in the IL-13/IL-4 space and the absence of disclosed exclusivity or pricing data, limiting full investment assessment.

1 total filings
· daily

New Drug Approvals (Original) — June 12, 2026

The FDA approval stream for June 12, 2026, consisted entirely of 9 biosimilar/‘Other’ approvals, with zero NMEs, biosimilars (as formally designated), or label expansions. The dominant therapeutic area theme is a multi-sponsor tofacitinib citrate biosimilar cluster (five separate approvals on June 9), which signals an imminent and deep erosion of Pfizer’s Xeljanz franchise in immunology. Propranolol hydrochloride (PAI Holdings) adds to the generic beta-blocker landscape, while Gallium GA-68 gozetotide (Radiomedix) and gadobutrol (Zenara) represent diagnostic/biosimilar imaging contrasts. The highest-conviction bearish signal is the tofacitinib wave, which will pressure Xeljanz pricing and market share across RA, UC, and PsO. A key risk is the near-term PEG pricing floor for these small-molecule generics, with IRA Medicare negotiation starting at year 9 for small molecules.

9 total filings
· daily

Federal Construction & Infrastructure Contracts — June 12, 2026

Over a single-day period in June 2026, federal construction and infrastructure contracting totaled $322.4 million, entirely allocated to a civilian agency (Department of State) with no defense-related awards. The sole contract of the period—a $322.4M firm-fixed-price award to Caddell Construction Co. (DE), LLC for the Rio New Consulate Compound—carries a neutral signal (strength 5/10, materiality 6/10). While the competitive win under full-and-open competition suggests Caddell’s established capabilities, the fixed-price structure transfers meaningful cost-overrun risk to the contractor, particularly on a large, long-duration (4.6-year) international construction project. The absence of set-asides or sole-source awards indicates a competitive process, but also no immediate concentration or moat signal. The key risk to monitor is execution on pricing and potential cost overruns in a foreign construction environment.

1 total filings
· daily

Defense Manufacturing Contracts — June 12, 2026

This digest covers a single $99.6 million civilian contract awarded by the Department of Commerce (NOAA) to JAG KETCHIKAN, LLC for the modernization of the NOAA Ship Henry B. Bigelow, with zero defense-related obligations in the period. The dominant theme is NOAA's investment in marine research infrastructure, which signals stable or growing funding for ship repair and modernization. The highest-conviction signal is neutral: the contract provides a clear, three-year revenue stream for JAG KETCHIKAN, but the firm-fixed-price structure introduces execution risk. A key watch item is JAG KETCHIKAN's financial capacity to manage this large, single-award contract without cost overruns, given its small business status.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 12, 2026

Over a single-day period, HHS awarded $217.3 million in two civilian contracts, with zero defense exposure. The dominant theme is government health security and pandemic-era R&D, led by a $133.5 million firm-fixed-price delivery order to Partner Therapeutics for Leukine, which carries strong near-term revenue visibility with $83.5 million already outlaid. A second, neutral-signal $83.8 million CDC contract to ABT Global for COVID-19 mental health research is largely completed ($80.9M outlaid) and provides no forward revenue. Key risk: Partner Therapeutics' contract is tied to HHS/ASPR medical preparedness priorities, which could face budget pressure under a Continuing Resolution, while ABT Global's high subaward rate (63%) signals reliance on partners rather than core capabilities.

2 total filings
· daily

New Federal Contractors — June 12, 2026

This digest covers $1.85 billion in new federal contract obligations awarded between June 12, 2026 and June 12, 2026, though most contracts were awarded in prior years. The portfolio is overwhelmingly civilian (9 of 10 contracts), led by the Department of Health and Human Services (3 contracts, $386.7M) and General Services Administration (3 contracts, $864.6M). The single defense-related contract (MANTECH at $452M) is the largest award and provides multi-year R&D revenue visibility. The highest-conviction signal is the bullish $133.5M firm-fixed-price award to Partner Therapeutics for Leukine, a pharmaceutical preparedness contract with $83.5M already funded. A key risk is the $322.4M firm-fixed-price State Department consulate contract to Caddell Construction, which carries execution risk on a complex overseas project.

10 total filings
· daily

Significant Contract Modifications ($10M+) — June 12, 2026

This digest of 10 significant contract modifications, totaling $1.85 billion, reveals a pronounced civilian-agency bias, with only one defense-related award. The dominant theme is sustained federal investment in IT modernization, R&D, and infrastructure, led by the General Services Administration (GSA), Department of Health and Human Services (HHS), and Department of State. The highest-conviction signal is a $133.5 million firm-fixed-price award to Partner Therapeutics for Leukine, a medical preparedness pharmaceutical, reflecting durable HHS/ASPR priorities. A key risk is the concentration of large, fixed-price contracts (e.g., Caddell Construction's $322.4M State Department project, JAG KETCHIKAN's $99.6M NOAA ship modernization) that transfer cost overrun risk to contractors, demanding close execution monitoring.

10 total filings
· daily

Contract Option Exercises — June 12, 2026

This digest covers 10 contract option exercises totaling $1.85B, with only 1 defense-related award (10% of total), reflecting a heavily civilian-skewed procurement stream. The dominant theme is civilian agency IT and R&D services, led by a $452M GSA FEDSIM award to MANTECH and a $322M Department of State construction contract to CADDELL. The highest-conviction signal is a $133.5M firm-fixed-price award to PARTNER THERAPEUTICS for Leukine, a pharmaceutical product, which offers strong near-term revenue visibility for this private company. Key risks include execution risk on fixed-price contracts (CADDELL, PERATON, MAXIMUS) and the absence of defense-related awards, which limits exposure to NDAA-prioritized spending. Investors should watch for follow-on awards from GSA FEDSIM and IRS IT modernization as indicators of civilian agency budget stability.

10 total filings
· daily

Federal Professional Services Contracts — June 12, 2026

This digest covers a single $167.3 million civilian professional services award to ACUMEN LLC from the Centers for Medicare and Medicaid Services (CMS) under the DATALINK program, representing the entire period's obligation. With zero defense-related contracts, the stream is entirely civilian, highlighting a concentrated bet on healthcare administrative consulting. The highest-conviction signal is ACUMEN's strong execution, with 89.5% of the total obligation already outlayed, providing multi-year revenue visibility through September 2026. A key risk is the time-and-materials pricing structure, which introduces margin uncertainty for the contractor and cost risk for the government, while the lack of set-aside suggests competitive merit but no structural moat. Investors should watch for any modifications or new task orders that could expand the total obligation, as well as CMS budget allocations for administrative consulting in future fiscal years.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — June 12, 2026

Over a single day, June 12, 2026, three civilian-agency IT contracts totaling $498.1M were awarded, with zero defense exposure. The dominant theme is stable, multi-year IT modernization and support services for the GSA and NIH, led by SAIC ($290.8M for EPA end-user support), Peraton ($121.6M for GSA application development), and CTIS ($85.6M for NIH cancer informatics). The highest-conviction signal is Peraton’s fixed-price BPA call, which offers predictable revenue but shifts execution risk to the contractor. A key risk is SAIC’s negative outlay (-$1.4M) on its 2017 contract, which may indicate past underperformance or funding adjustments, though the contract ended in 2022 with no current revenue impact. All three contracts are neutral in signal strength (5/10), reflecting competitive wins with no clear bullish or bearish catalysts.

3 total filings
· daily

All HHS Contracts — June 12, 2026

This digest covers $470.3 million in HHS contract obligations from June 12, 2026, with zero defense-related awards, highlighting a purely civilian health-sector procurement environment. The dominant theme is administrative and IT support for CMS and NIH, with the largest contract ($167.3M to ACUMEN LLC for CMS DATALINK) showing 89.5% outlayed, signaling strong recurring revenue but neutral forward visibility. The highest-conviction signal is the $133.5M firm-fixed-price award to Partner Therapeutics for Leukine, which offers high margin potential and medical preparedness alignment. Key risks include the expired COVID-19 research contract at ABT GLOBAL ($83.8M) and the time-and-materials pricing risk at ACUMEN, which introduces margin uncertainty. Investors should watch CMS budget allocations and ASPR follow-on procurement for Leukine as near-term catalysts.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — June 12, 2026

This digest covers $1.49B in mega-contracts awarded across six transactions, with a pronounced civilian agency tilt—only one of six is defense-related (SAIC's EPA support via GSA, which is civilian in nature). The dominant theme is stable, multi-year civilian IT and professional services spending, led by MANTECH's $452M GSA R&D award and CADDELL's $322M State Department consulate construction contract. The highest-conviction signal is Partner Therapeutics' $133.5M firm-fixed-price delivery order for Leukine, reflecting durable HHS medical preparedness priorities. Key risks include execution exposure on fixed-price construction and IT contracts (CADDELL, Peraton) and the absence of defense-driven growth catalysts in this cohort, which may limit upside for pure-play defense contractors.

6 total filings